Assenagon Asset Management S.A. Sells 160,429 Shares of Inogen, Inc. (NASDAQ:INGN)

Assenagon Asset Management S.A. lowered its stake in shares of Inogen, Inc. (NASDAQ:INGN) by 68.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,452 shares of the medical technology company’s stock after selling 160,429 shares during the period. Assenagon Asset Management S.A. owned approximately 0.31% of Inogen worth $683,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of INGN. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after acquiring an additional 132,287 shares during the last quarter. AQR Capital Management LLC raised its holdings in Inogen by 29.3% in the second quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after purchasing an additional 129,307 shares during the period. Sanctuary Advisors LLC acquired a new stake in Inogen in the second quarter worth $651,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Inogen in the 2nd quarter valued at $457,000. Finally, Royce & Associates LP grew its holdings in shares of Inogen by 167.4% in the 3rd quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company’s stock valued at $503,000 after buying an additional 32,482 shares during the period. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Inogen Stock Up 3.2 %

Shares of NASDAQ:INGN opened at $11.44 on Friday. The firm has a market cap of $272.48 million, a price-to-earnings ratio of -5.08 and a beta of 1.02. Inogen, Inc. has a 12 month low of $5.37 and a 12 month high of $13.33. The company’s fifty day simple moving average is $9.59 and its 200 day simple moving average is $10.02.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, November 7th. The medical technology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.26. The company had revenue of $88.83 million for the quarter, compared to analyst estimates of $83.68 million. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. During the same period in the previous year, the company posted ($1.97) earnings per share. Research analysts expect that Inogen, Inc. will post -1.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

INGN has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Tuesday, January 14th. StockNews.com cut Inogen from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.